共 2 条
- [2] Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. (vol 85, pg 125, 2019) ANNALS OF NEUROLOGY, 2024, 95 (02) : 417 - 417